Revolutionizing patient outcomes in cancer therapies

Oncological cell therapies are driving the next generation of cancer treatments. As CAR-T entered mainstream health services, high costs for treatments and restricted patient pools have confined the therapy to a late-stage treatment and limited the market potential that this revolutionary field can have.

The Onco Cell Therapy Summit (formerly the CAR-T Congress) in Boston on April 7-8 will have four tracks dedicated to addressing critical challenges in CAR-T R&D, Alternative Therapies R&D, Vein-to-Vein manufacturing, and commercialization, regulation and safety. Bringing together industry and academia working in CAR-T, TILs, NK and TCR to identify unmet community needs.

Speaker highlights include:

• Discover the next generation for immuno-oncology from Professor Carl June

• Crystal Mackall shares insights on developing methodology for overcoming tumor resistance to increase efficacy against solid tumors

• Explore the hurdles that are in place whilst targeting solid tumors and how to clear the route for an off the shelf therapy with Peter Emtage, Kite and Pascal Touchon, Atara Biotherapeutics

• Larissa Lapteva, FDA shares how to establish best practice for REMS development improved market access

Interested in attending?

Don't miss our super early bird rate, save over $800 only until 24 January 2020!

Best wishes,

The OCTS Team

Join the leading biotech's, pharma companies & academics disrupting the market